We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cerebral GABA and Fear Conditioning in PTSD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01800383
Recruitment Status : Unknown
Verified March 2016 by Isabelle Rosso, McLean Hospital.
Recruitment status was:  Recruiting
First Posted : February 27, 2013
Last Update Posted : March 16, 2016
Mclean Hospital
Information provided by (Responsible Party):
Isabelle Rosso, McLean Hospital

Brief Summary:

Posttraumatic stress disorder (PTSD) is a common and debilitating neuropsychiatric disorder in which an acute fear response to a traumatic event does not abate. This failure to recover from trauma is thought to be due at least in part to a deficit in learning not to fear situations and stimuli previously associated with the trauma (i.e., specifically due to a failure of extinction recall). Pavlovian fear conditioning can be simulated and measured experimentally in humans using a 2-day fear conditioning paradigm developed by our group, wherein conditioning and extinction learning phases are conducted on Day 1, and extinction recall is tested on Day 2.

Recent functional magnetic resonance imaging (fMRI) evidence indicates that PTSD is associated with hyper-responsivity of the insular cortex and hyporesponsivity of the ventromedial prefrontal cortex (VMPFC) during exposure to fear-inducing stimuli, consistent with altered excitability of brain regions mediating fear conditioning and extinction. As the brain's principal inhibitory neurotransmitter, GABA exerts a prominent role in modulating neuronal excitability. Interestingly, there are reports that adjunctive treatment with GABA-enhancing antiepileptics is efficacious in PTSD. There is also evidence, albeit inconsistent, that lower serum GABA levels predict a more chronic course of the illness. However, it is unclear whether serum levels accurately reflect brain GABA, which may contribute to inconsistency of serum findings. Moreover, it is possible that GABA alterations may vary in their presence, nature and significance across brain regions implicated in PTSD. The proposed study will examine the relationship of PTSD symptoms and behavioral fear conditioning deficits with regional brain gamma-aminobutyric acid (GABA) using proton magnetic resonance spectroscopy (1H-MRS).

We have the following aims and hypotheses:

  1. To determine whether GABA alterations are associated with the categorical diagnosis of PTSD and not merely exposure to trauma. It is hypothesized that PTSD will be associated with higher GABA in VMPFC and lower GABA in the right insula.
  2. To determine whether GABA levels are significantly associated with dimensional measures of PTSD symptom severity and individual symptom dimensions. It is predicted that higher GABA in the VMPFC and lower GABA in the right anterior insula will be associated with greater total symptom severity.
  3. To determine whether GABA in VMPFC and right anterior insula are significantly associated with measures of extinction recall failure and anxiety sensitivity in PTSD. It is hypothesized that VMPFC GABA will be positively correlated with skin conductance response to a conditioned stimulus that had previously been extinguished and insula GABA will be negatively correlated with anxiety sensitivity.

Condition or disease
Stress Disorders, Post-Traumatic

Study Type : Observational
Estimated Enrollment : 93 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Study Start Date : February 2013
Estimated Primary Completion Date : February 2018
Estimated Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

No Axis I psychiatric disorder and no trauma exposure
Trauma-Exposed Normal Control
History of trauma exposure and subthreshold PTSD symptoms.
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised

Primary Outcome Measures :
  1. Regional brain gamma-aminobutyric acid (GABA) levels in the ventromedial prefrontal cortex (VMPFC), right anterior insula, and right posterior temporal cortex [ Time Frame: Measured on the day of the MRI scan ]
    Single voxel 3T H-MRS cortex using a MEGAPRESS sequence will be used to detect and quantify GABA in these brain regions.

  2. Regional brain glutamate metabolism in the ventromedial prefrontal cortex (VMPFC), right anterior insula, and right posterior temporal cortex [ Time Frame: Measured on the day of the MRI scan ]
    Single voxel 3T H-MRS cortex using a 2DJPRESS sequence at 3T will be used to detect and quantify glutamate and glutamine in these brain regions.

  3. Regional brain neuronal integrity in the ventromedial prefrontal cortex (VMPFC), right anterior insula, and right posterior temporal cortex [ Time Frame: Measured on the day of the MRI scan ]
    Single voxel 3T H-MRS cortex using a 2DJPRESS sequence at 3T will be used to detect and quantify N-acetyl aspartate in these brain regions.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects will be between the ages of 20 and 50 years. These will include 31 subjects meeting DSM-IV criteria for PTSD, 31 trauma-exposed healthy subjects, and 31 healthy comparison (HC) subjects without any trauma exposure.

Inclusion Criteria:

  • 20-50 years of age
  • right-handed
  • DSM-IV diagnosis consistent with group assignment
  • groups to be matched for age, sex, education, race/ethnicity
  • ability to provide written informed consent
  • groups to be matched on proportion of female subjects in follicular/luteal menstrual phases.

Exclusion Criteria:

  • Medical condition that would confound results
  • history of seizures or head trauma with loss of consciousness
  • exposure to psychotropic medications within 4 weeks of study (8 weeks for fluoxetine)
  • metal implants, claustrophobia or other Magnetic Resonance Imaging (MRI) exclusions
  • positive urine toxicology or human chorionic gonadotropin (HCG) status on scan day
  • history of psychotic disorder, bipolar disorder, eating disorder, mental retardation, or pervasive developmental disorder; history of meeting full criteria for non-PTSD anxiety disorder.
  • PTSD and trauma subjects will be matched in terms of comorbid depressive disorder, not to exceed 50%. Trauma-exposed subjects will have a history of trauma exposure and will not meet criteria for PTSD. Non-traumatized healthy subjects will have no history of Axis I psychiatric disorder and no trauma exposure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01800383

Contact: Lauren Demers 617-855-2268 adlab@mclean.harvard.edu

United States, Massachusetts
McLean Hospital Recruiting
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Isabelle Rosso
Mclean Hospital
Principal Investigator: Isabelle Rosso, PhD Mclean Hospital

Responsible Party: Isabelle Rosso, Director, Anxiety and Traumatic Stress Disorders Laboratory, McLean Hospital
ClinicalTrials.gov Identifier: NCT01800383     History of Changes
Other Study ID Numbers: MH096987-01A1
First Posted: February 27, 2013    Key Record Dates
Last Update Posted: March 16, 2016
Last Verified: March 2016

Keywords provided by Isabelle Rosso, McLean Hospital:
posttraumatic stress disorder
fear conditioning
proton magnetic resonance spectroscopy

Additional relevant MeSH terms:
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders